PTJ
PNT

Paul Tudor Jones’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Paul Tudor Jones’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,742
Closed -$478K – 2999
2023
Q2 		$478K Buy
+52,742
New +$465K 0.01% 1730
2022
Q4 		– Sell
-10,282
Closed -$79K – 2963
2022
Q3 		$79K Buy
+10,282
New +$87.3K ﹤0.01% 2164

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's PNT Position: Q3 2023 in Review

Paul Tudor Jones sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 52,742 shares — an estimated $478K sold.

Paul Tudor Jones first reported a position in PNT in Q3 2022 and held it in 2 quarters. The position peaked at $478K in Q2 2023. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Paul Tudor Jones reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 52,742 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $478K.
  • Paul Tudor Jones first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Paul Tudor Jones's POINT Biopharma Global Inc. Common Stock position peaked at $478K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Tudor Investment Corp's 13F filing for Q3 2023, filed 15 Nov 2023.